Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Molecular Pathology, Diagnostics, and Therapeutics of Kidney Disease
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Pathology, Diagnostics, and Therapeutics of Kidney Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 3186

Special Issue Editors

Dr. Evangelia Dounousi

E-Mail Website
Guest Editor
Department of Nephrology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece
Interests: kidney disease; biomarkers; oxidative stress
Special Issues, Collections and Topics in MDPI journals
Dr. Vassilios Liakopoulos

E-Mail Website
Co-Guest Editor
2nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece
Interests: chronic kidney disease; cardiovascular disease; vascular calcification; diabetes mellitus; hemodialysis; peritoneal dialysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Kidney diseases have emerged as a major global health problem, with a profound impact on patients and healthcare systems. Kidney disease research has advanced significantly in recent years, with targeted treatment options for a number of primary kidney diseases as well as improved therapies for managing chronic kidney disease and its complications. There have been considerable advancements in the identification of specific biomarkers for early diagnosis, prognosis, and monitoring. The development of kidney organoids has created new opportunities for studying kidney development, disease mechanisms, and drug testing. Additionally, artificial intelligence and machine learning algorithms are being applied to datasets to improve the diagnosis and management of kidney diseases. This special issue aims to highlight the most recent developments, cutting-edge research, and novel interventions that are contributing to a better understanding of kidney disease and improved patient outcomes. By integrating a wide range of research papers, clinical trials, and expert opinions, we aim to address the key challenges in the field and foster progress towards better management of kidney diseases.

We invite submissions on a variety of topics related to kidney disease, including but not limited to:

  1. Novel diagnostic techniques and biomarkers
  2. Advances in renal imaging and pathology
  3. Precision Medicine in Nephrology
  4. Artificial Intelligence and Machine Learning in Nephrology
  5. Novel Insights into Acute Kidney Injury
  6. Emerging therapies for chronic kidney disease
  7. Recent advancements in renal replacement therapies
  8. Challenges and advances in kidney transplantation

We welcome contributions that address these and other topics related to kidney disease.

This Special Issue is supervised by Dr. Evangelia Dounousi (University of Ioannina) and assisted by Dr. Vassilios Liakopoulos (Aristotle University of Thessaloniki) and our Topical Advisory Panel Member Dr. Stamellou Eleni (RWTH Aachen University).

Dr. Evangelia Dounousi
Dr. Vassilios Liakopoulos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • kidney disease
  • advances
  • improved outcomes
  • precision medicine
  • therapeutic approaches

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

13 pages, 1080 KiB  
Article
The Value of Urinary NGAL, KIM-1, and IL-18 Measurements in the Early Detection of Kidney Injury in Oncologic Patients Treated with Cisplatin-Based Chemotherapy
by Dawid Szumilas, Aleksander Jerzy Owczarek, Aniceta Brzozowska, Zofia Irena Niemir, Magdalena Olszanecka-Glinianowicz and Jerzy Chudek
Int. J. Mol. Sci. 2024, 25(2), 1074; https://doi.org/10.3390/ijms25021074 - 16 Jan 2024
Viewed by 827
Abstract
Cisplatin is still a widely used anticancer drug characterized by significant nephrotoxicity. Acute kidney injury (AKI), diagnosed based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, has limitations, including a delayed increase in creatinine. We determined the usefulness of neutrophil gelatinase-associated lipocalin [...] Read more.
Cisplatin is still a widely used anticancer drug characterized by significant nephrotoxicity. Acute kidney injury (AKI), diagnosed based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, has limitations, including a delayed increase in creatinine. We determined the usefulness of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) in diagnosing AKI according to the KDIGO criteria in patients treated with cisplatin. We recruited 21 subjects starting cisplatin-based chemotherapy (Cisplatin-based group) and 11 treated with carboplatin-based chemotherapy or 5-fluorouracil regimens (non-cisplatin-based group). Blood and urine samples were collected during four subsequent cycles of chemotherapy (68 and 38 cycles, respectively). AKI occurred in four patients in the cisplatin-based group (5.9% of 68 cisplatin-based chemotherapy cycles). Among them, three urinary markers were increased by over 100% in two cases, two in one case and one in another. A doubling of at least one investigated parameter was observed more frequently during cisplatin-based chemotherapy (80.3% vs. 52.8%; OR = 3.65, 95% CI: 1.49–8.90; p < 0.01). The doubling of at least one new urinary AKI marker was more common in patients receiving cisplatin and frequently was not associated with overt AKI. Thus, a subclinical kidney injury detected by these markers occurs more frequently than deterioration in kidney function stated with creatinine changes. Full article
(This article belongs to the Special Issue Molecular Pathology, Diagnostics, and Therapeutics of Kidney Disease)
►▼ Show Figures

Figure 1

12 pages, 1312 KiB  
Article
Efficiency of Platelet Transfusion in Patients with Moderate-to-Severe Chronic Kidney Disease and Thrombocytopenia
by Sevigean Ali, Mihaela Botnarciuc, Lavinia Carmen Daba, Sorina Ispas, Alina Mihaela Stanigut, Camelia Pana, Marian-Catalin Burcila and Liliana-Ana Tuta
Int. J. Mol. Sci. 2023, 24(21), 15895; https://doi.org/10.3390/ijms242115895 - 02 Nov 2023
Viewed by 1641
Abstract
There have been relatively few studies revealing a decreased platelet count in chronic kidney disease (CKD). Although this hematological abnormality is not as well documented as renal anemia, platelet functions are altered in the uremic environment and there is an increased risk of [...] Read more.
There have been relatively few studies revealing a decreased platelet count in chronic kidney disease (CKD). Although this hematological abnormality is not as well documented as renal anemia, platelet functions are altered in the uremic environment and there is an increased risk of bleeding. The aim of this study was to assess the effectiveness of the administration of platelet concentrate in CKD based on how patient prognosis was influenced by platelet transfusion therapy. The study monitored 104 patients with CKD and thrombocytopenia who received platelet transfusion during their hospitalization in the period from 2015 to 2021. The complete blood cell count, serum urea and creatinine, and inflammatory status were tested upon admission. The number of transfused platelet units were considered for each patient. A Kruskal–Wallis H test showed that for one transfused platelet unit, the distribution of the number of platelets (×103/µL) was the same across the categories of associated diagnoses, which was seen as possible risk factors for thrombocytopenia, including liver cirrhosis and urosepsis. With a single exception, all patients exceeded the critical threshold of 20 × 103/µL and 14 patients remained under 50 × 103/µL. Even though our patients exceeded the critical threshold of platelet numbers, in patients with multiple comorbidities, severe, uncontrolled hemorrhages could not be prevented in 4.83% of cases. Full article
(This article belongs to the Special Issue Molecular Pathology, Diagnostics, and Therapeutics of Kidney Disease)
►▼ Show Figures

Figure 1

Other

Jump to: Research

7 pages, 525 KiB  
Case Report
The Phenotypic Variability Associated with Hepatocyte Nuclear Factor 1B Genetic Defects Poses Challenges in Both Diagnosis and Therapy
by Ioannis Petrakis, Maria Sfakiotaki, Maria Bitsori, Eleni Drosataki, Kleio Dermitzaki, Christos Pleros, Ariadni Androvitsanea, Dimitrios Samonakis, Amalia Sertedaki, Paraskevi Xekouki, Emmanouil Galanakis and Kostas Stylianou
Int. J. Mol. Sci. 2024, 25(8), 4552; https://doi.org/10.3390/ijms25084552 - 22 Apr 2024
Viewed by 346
Abstract
The evolving landscape of clinical genetics is becoming increasingly relevant in the field of nephrology. HNF1B-associated renal disease presents with a diverse array of renal and extrarenal manifestations, prominently featuring cystic kidney disease and diabetes mellitus. For the genetic analyses, whole exome sequencing [...] Read more.
The evolving landscape of clinical genetics is becoming increasingly relevant in the field of nephrology. HNF1B-associated renal disease presents with a diverse array of renal and extrarenal manifestations, prominently featuring cystic kidney disease and diabetes mellitus. For the genetic analyses, whole exome sequencing (WES) and multiplex ligation-dependent probe amplification (MLPA) were performed. Bioinformatics analysis was performed with Ingenuity Clinical Insights software (Qiagen). The patient’s electronic record was utilized after receiving informed consent. In this report, we present seven cases of HNF1B-associated kidney disease, each featuring distinct genetic abnormalities and displaying diverse extrarenal manifestations. Over 12 years, the mean decline in eGFR averaged −2.22 ± 0.7 mL/min/1.73 m2. Diabetes mellitus was present in five patients, kidney dysplastic lesions in six patients, pancreatic dysplasia, hypomagnesemia and abnormal liver function tests in three patients each. This case series emphasizes the phenotypic variability and the fast decline in kidney function associated with HNF-1B-related disease. Additionally, it underscores that complex clinical presentations may have a retrospectively straightforward explanation through the use of diverse genetic analytical tools. Full article
(This article belongs to the Special Issue Molecular Pathology, Diagnostics, and Therapeutics of Kidney Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop